RedHill Biopharma

RedHill Biopharma is a specialty biopharmaceutical company focused on gastrointestinal and infectious diseases, with a pipeline spanning oncology and pulmonary indications. It commercialized Talicia (H. pylori eradication) and Aemcolo (travelers' diarrhea) in the U.S. and, on August 31, 2026, announced the divestiture of its Talicia business to a subsidiary of Apotex Health for $18 million upfront plus up to $35 million in worldwide net-sales milestones, using the proceeds to fund U.S. pipeline expansion. Pipeline candidates include opaganib, RHB-107 (upamostat), RHB-104, RHB-102 (Bekinda), and RHB-204 (Phase 3 for pulmonary Mycobacterium avium complex disease).